Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Experts Assess Infection Risks for Patients on Biologics Experts Assess Infection Risks for Patients on Biologics
A group of experts have summarized and made recommendations about recent findings regarding infections that can occur during treatment for rheumatoid arthritis and psoriatic arthritis.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 8, 2020 Category: Infectious Diseases Tags: Rheumatology News Source Type: news

Pregnancy Studies on Psoriasis, PsA Medications Pick Up Pregnancy Studies on Psoriasis, PsA Medications Pick Up
Pregnancy outcomes data are increasingly emerging but dermatologists, rheumatologists, and their female patients with psoriasis and psoriatic arthritis (PsA) want much more.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 2, 2020 Category: Dermatology Tags: Ob/Gyn & Women ' s Health News Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Simponi Aria (golimumab) Approved by the FDA for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Simponi Aria (golimumab) for patients 2 years of age and older for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 30, 2020 Category: Drugs & Pharmacology Source Type: news

Secukinumab Not Superior to Adalimumab in Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - September 26, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news

Key discovery in psoriatic arthritis points way for developing targeted treatments
(University of Oxford) The strongest evidence yet of a single cause for psoriatic arthritis has been discovered by researchers. The disease may be activated by the same trigger in different patients which, if identified, could move towards creating therapies that would prevent psoriatic arthritis, and potentially providing a cure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2020 Category: International Medicine & Public Health Source Type: news

The Long Road to a PsA Prevention Trial The Long Road to a PsA Prevention Trial
About one third of all patients with psoriasis will develop psoriatic arthritis in their lifetime. With no definitive blood test for diagnosis, prevention trials are key to identifying high-risk groups.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 5, 2020 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Ixekizumab in psoriatic arthritis: more QALYs, lower cost in Spain
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 31, 2020 Category: Drugs & Pharmacology Source Type: news

Tumor Necrosis Factor Alpha Inhibitors May Pose Risk in Ankylosing Spondylitis and Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 21, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Tremfya (Guselkumab) for Psoriatic Arthritis FDA Approves Tremfya (Guselkumab) for Psoriatic Arthritis
Guselkumab, first approved for adults with plaque psoriasis in 2017, has now been approved for adults with active psoriatic arthritis (PsA). The FDA based its approval on two pivotal phase 3 trials.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 15, 2020 Category: Dermatology Tags: Rheumatology News Source Type: news

TREMFYA ® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA. The safety and efficacy of TREMFYA in PsA have b...
Source: Johnson and Johnson - July 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
In two Phase 3 clinical trials, TREMFYA significantly improved signs and symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis TREMFYA is the first and only biologic approved for the treatment of active psoriatic arthritis t... Biopharmaceuticals, FDA Janssen Pharmaceutical, Johnson & Johnson, TREMFYA, guselkumab, PsA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 14, 2020 Category: Pharmaceuticals Source Type: news

Tremfya (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
HORSHAM, PA, July 14, 2020– The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 14, 2020 Category: Drugs & Pharmacology Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

TNF Inhibitor Plus Methotrexate Surpassed Monotherapy in PsA TNF Inhibitor Plus Methotrexate Surpassed Monotherapy in PsA
The addition of a TNF inhibitor to the treatment regimen of patients with psoriatic arthritis (PsA) improves the achievement of minimal disease activity, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Upadacitinib Looks Effective for Psoriatic Arthritis Upadacitinib Looks Effective for Psoriatic Arthritis
Findings from a pair of phase 3 trials support use of the JAK inhibitor for psoriatic arthritis; it has already been approved for rheumatoid arthritis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

BIOCAD presents results of clinical trial proving efficacy of netakimab at EULAR 2020
(BIOCAD) BIOCAD presents results of clinical trial proving efficacy of netakimab in the treatment of psoriatic arthritis at the Annual European Congress of Rheumatology (EULAR 2020). Four abstracts present the results from an international randomized double-blind phase 3 clinical trial (PATERA) which demonstrate netakimab decreases disease activity and reduces skin manifestation of psoriatic arthritis through 24 weeks of therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2020 Category: International Medicine & Public Health Source Type: news

FDA Approves Ixekizumab (Taltz) for Nonradiographic axSpA FDA Approves Ixekizumab (Taltz) for Nonradiographic axSpA
The monoclonal interleukin-17A antagonist has three other indications: ankylosing spondylitis in adults, psoriatic arthritis in adults, and plaque psoriasis in adults and children age 6 and older.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 1, 2020 Category: Dermatology Tags: Rheumatology News Source Type: news

Arthritis: Which condition makes you more vulnerable to psoriatic arthritis?
PSORIATIC arthritis is a long-term condition that may result in deformed joints. The auto-immune condition can stem from the skin condition psoriasis. Here's everything you need to know. (Source: Daily Express - Health)
Source: Daily Express - Health - May 31, 2020 Category: Consumer Health News Source Type: news

Weight management, acupuncture and more: Natural remedies that help relieve arthritis pain
(Natural News) Arthritis is a general term for a group of degenerative conditions that target the joints and the tissues that surround the joints. There are several types of arthritis including osteoarthritis, rheumatoid arthritis and psoriatic arthritis. Although each type is influenced by unique factors, arthritis is generally marked by chronic inflammation in the hands,... (Source: NaturalNews.com)
Source: NaturalNews.com - May 4, 2020 Category: Consumer Health News Source Type: news

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion av...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Modifiable Risk Factors for Development of Psoriatic Arthritis Modifiable Risk Factors for Development of Psoriatic Arthritis
This study examined weight reduction as well as smoking as potential modifiable risk factors for PsA.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Apremilast less costly in biologic-na ïve patients with psoriatic arthritis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 29, 2020 Category: Drugs & Pharmacology Source Type: news

Evaluating risk of cancer in patients with psoriasis, psoriatic arthritis
(JAMA Network) This observational study was a systematic review and meta-analysis that included 112 studies and examined the association between risk of cancer in patients with psoriasis or psoriatic arthritis, including the risk of specific cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2020 Category: Cancer & Oncology Source Type: news

Weight Loss and Severity of Psoriasis or Psoriatic Arthritis Weight Loss and Severity of Psoriasis or Psoriatic Arthritis
This review examined the impact of weight loss on pre-existing psoriasis or psoriatic arthritis. Might losing weight prevent the onset of psoriasis in obese individuals?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 10, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

FDA approves Pfizer's biosimilar, ABRILADA ™ (adalimumab-afzb) for multiple inflammatory conditions
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2) (Source: World Pharma News)
Source: World Pharma News - December 2, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Rates of Joint Surgery Higher With Psoriatic Arthritis
MONDAY, Nov. 25, 2019 -- The five-year incidence rate of joint surgery in psoriatic arthritis (PsA) patients is twice as high as in the general population, and this rate has remained steady over time, according to a study published in the November... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 25, 2019 Category: Pharmaceuticals Source Type: news

Amgen completes acquisition of Otezla ® (apremilast)
Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (NASDAQ:CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE:BMY), which was completed on Nov. 20. (Source: World Pharma News)
Source: World Pharma News - November 21, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the 52-w... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 12, 2019 Category: Pharmaceuticals Source Type: news

ACR: Age at Psoriasis Onset Sets Course for Psoriatic Arthritis
TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 12, 2019 Category: Pharmaceuticals Source Type: news

TREMFYA ® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies
Findings from the DISCOVER-1 and DISCOVER-2 studies are presented, for the first time, at the 2019 American College of Rheumatology and Association of Rheumatology Professionals Annual MeetingThese are the first Phase 3 results evaluating p19-specific IL-23 inhibition in active psoriatic arthritis (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 11, 2019 Category: Pharmaceuticals Source Type: news

Medical News Today: Can you prevent psoriatic arthritis?
It is impossible to know who will develop psoriatic arthritis, though it usually affects people who already have psoriasis. Learn about whether people can prevent psoriatic arthritis here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 4, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Novartis Cosentyx ® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
Novartis, a leader in rheumatology and immuno-dermatology, announced results from the EXCEED head-to-head trial comparing Cosentyx® (secukinumab) to Humira®* (adalimumab) in patients with active psoriatic arthritis (PsA)[1]. While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira®*[1]. (Source: World Pharma News)
Source: World Pharma News - November 4, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Medical News Today: What are the complications of psoriatic arthritis?
There are many possible complications of psoriatic arthritis, including uveitis, kidney disease, and depression. Learn about the risks and preventive steps here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 30, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Medical News Today: What to know about distal interphalangeal joint pain
Distal interphalangeal joint pain is often due to osteoarthritis or psoriatic arthritis. Learn more about the causes and their symptoms in this article. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 29, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Biologic DMARD Treatment and Bone Strength and Structure in Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - October 17, 2019 Category: Orthopaedics Tags: CME Article Source Type: news

Effect of DMARDs on Bone Structure and Strength in PsA Effect of DMARDs on Bone Structure and Strength in PsA
In what ways might DMARD treatment impact bone structure and strength in patients with psoriatic arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis
The interleukin-17A inhibitor is now indicated for the treatment of adults with active ankylosing spondylitis, as well as for certain patients with plaque psoriasis and active psoriatic arthritis.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 26, 2019 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Amgen To Acquire Otezla(R) For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
Innovative Therapy Will Strengthen Amgen's Inflammation Portfolio for Patients Around the World Acquisition Expected to Accelerate Growth and Enhance Value for Amgen Shareholders Amgen to Host Call With Investors at 5 a.m. PT (8 a.m. ET) THOUSAND ... Biopharmaceuticals, Acquisitions Amgen, Celgene, Otezla, apremilast, psoriasis, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2019 Category: Pharmaceuticals Source Type: news

Amgen to acquire Otezla ® for $13.4 billion in cash
Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits. (Source: World Pharma News)
Source: World Pharma News - August 26, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

August 2019
Period Problems : Fibroids, Endometriosis, and Other Issues Bulging Veins : What to Do About Varicose Veins Dr. Stacey Missmer on Painful Periods in Teens More Steps for Better Health What is Psoriatic Arthritis? Urologic Diseases (Source: NIH News in Health)
Source: NIH News in Health - August 4, 2019 Category: Consumer Health News Source Type: news

Medical News Today: A guide to psoriatic arthritis medication
Medications can relieve the symptoms of psoriatic arthritis, slow disease progression, and reduce or prevent joint damage. We explore the current treatments and medication advances here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 24, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

August 2019
Period Problems : Fibroids, Endometriosis, and Other Issues Bulging Veins : What to Do About Varicose Veins Dr. Stacey Missmer on Painful Periods in Teens More Steps for Better Health What is Psoriatic Arthritis? Urologic Diseases (Source: NIH News in Health)
Source: NIH News in Health - July 24, 2019 Category: Consumer Health News Source Type: news

Long-Term Experience With Apremilast in Psoriatic Arthritis Long-Term Experience With Apremilast in Psoriatic Arthritis
A new analysis shows that apremilast may be safe and effective for longer-term treatment of psoriatic arthritis.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Medical News Today: What to know about Xeljanz
This article provides an overview of its uses, how it works, and side effect warnings. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 25, 2019 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news

BMS to divest Celgene drugs to speed delayed deal
Bristol-Myers Squibb said it is planning to sell Otezla, Celgene's treatment for certain types of psoriasis and psoriatic arthritis, in an effort to address Federal Trade Commission concerns about its pending merger with Celgene. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 24, 2019 Category: Pharmaceuticals Source Type: news

BMS to divest Celgene drug to speed delayed deal
Bristol-Myers Squibb said it is planning to sell Otezla, Celgene's treatment for certain types of psoriasis and psoriatic arthritis, in an effort to address Federal Trade Commission concerns about its pending merger with Celgene. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 24, 2019 Category: Pharmaceuticals Source Type: news